Literature DB >> 9826467

Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen.

S J Kim1, S N Bae, J H Kim, C J Kim, J K Jung.   

Abstract

OBJECTIVE: The purpose of this study was to determine the independent risk factors for resistance to EMA/CO chemotherapy in gestational trophoblastic tumor (GTT), to develop a more accurate scoring system for the evaluation of high-risk GTT patients.
METHODS: We performed a retrospective study and reviewed 165 GTT patients who received the EMA/CO regimen. Among these patients, 27 showed resistance to EMA/CO.
RESULTS: According to the univariate analysis of risk factors, tumor age, initial human chorionic gonadotropin level, metastatic site, number of metastatic organs, unplanned operation, gravidity, and inadequate previous chemotherapy all showed statistical significance. However, the results of the stepwise-Cox proportional hazards regression of prognostic factors using multivariate analysis showed statistical significance for tumor age, number of metastatic organs, metastatic site, and previously inadequate chemotherapy. The results of the stepwise logistic regression of prognostic factors showed tumor age and number of metastatic organs as significant. According to the performance of the fitted logistic regression model, the accuracy of predicted death and survival was 80.5%.
CONCLUSIONS: We determined that the following factors indicate a poor prognosis: (1) tumor age greater than 12 months, (2) number of metastatic organs greater 2, (3) incomplete previous treatment, including unplanned operation and inadequate chemotherapy. In patients with two and three of these factors, the death rates were 17.7 and 56.6%, respectively. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826467     DOI: 10.1006/gyno.1998.5161

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia.

Authors:  Adnan Aydiner; Serkan Keskin; Sinan Berkman; Ergin Bengisu; Huseyin Ridvan Ilhan; Faruk Tas; Erkan Topuz
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-23       Impact factor: 4.553

Review 2.  Gestational trophoblastic neoplasia: an update.

Authors:  Jacqueline M Morgan; John R Lurain
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

3.  Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5.

Authors:  Yuan Li; Yujia Kong; Xirun Wan; Fengzhi Feng; Tong Ren; Jun Zhao; Junjun Yang; Yang Xiang
Journal:  Oncologist       Date:  2021-09-09

Review 4.  Treatment of gestational trophoblastic tumors.

Authors:  John R Lurain
Journal:  Curr Treat Options Oncol       Date:  2002-04

Review 5.  Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.

Authors:  Mo'iad Alazzam; John Tidy; Raymond Osborne; Robert Coleman; Barry W Hancock; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2016-01-13

6.  The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia.

Authors:  Shizuka Sato; Eiko Yamamoto; Kaoru Niimi; Kazuhiko Ino; Kimihiro Nishino; Shiro Suzuki; Tomomi Kotani; Hiroaki Kajiyama; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2019-09-13       Impact factor: 3.402

7.  Current chemotherapeutic management of patients with gestational trophoblastic neoplasia.

Authors:  Taymaa May; Donald P Goldstein; Ross S Berkowitz
Journal:  Chemother Res Pract       Date:  2011-05-11

8.  Gestational Choriocarcinoma Presenting with Lacrimal Gland Metastasis: A First Reported Case.

Authors:  Naushad A B Ahamed; Khalid Sait; Nisreen Anfnan; Khader Farwan; S H M Nizamuddin; Saleh S Baeesa
Journal:  Case Rep Obstet Gynecol       Date:  2015-05-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.